Tegean Capital Management Has Raised Assured Guaranty LTD (AGO) Holding; Last Week Achillion Pharmaceuticals, Inc. (ACHN) Coverage

March 14, 2018 - By Adrian Erickson

Among 11 analysts covering Achillion Pharma (NASDAQ:ACHN), 6 have Buy rating, 0 Sell and 5 Hold. Therefore 55% are positive. Achillion Pharma had 27 analyst reports since August 13, 2015 according to SRatingsIntel. Robert W. Baird maintained it with “Hold” rating and $4.0 target in Monday, October 23 report. As per Friday, February 26, the company rating was upgraded by Robert W. Baird. Maxim Group maintained the shares of ACHN in report on Thursday, February 25 with “Buy” rating. The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has “Hold” rating given on Wednesday, February 7 by FBR Capital. The firm has “Buy” rating given on Friday, August 11 by Leerink Swann. The firm earned “Sell” rating on Thursday, July 14 by Chardan Capital Markets. The firm earned “Neutral” rating on Friday, November 4 by Chardan Capital Markets. Wedbush initiated it with “Outperform” rating and $13 target in Friday, September 23 report. The rating was downgraded by Robert W. Baird on Thursday, August 10 to “Neutral”. Maxim Group maintained the stock with “Buy” rating in Wednesday, August 9 report. See Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) latest ratings:

23/02/2018 Broker: FBR Capital Rating: Hold Maintain
07/02/2018 Broker: FBR Capital Rating: Hold New Target: $3.5 Initiate
08/02/2018 Broker: B. Riley & Co Rating: Neutral New Target: $3.5 Initiates Coverage On
11/12/2017 Broker: Leerink Swann Rating: Buy New Target: $5.0 Maintain
23/10/2017 Broker: Robert W. Baird Rating: Hold New Target: $4.0 Maintain

Tegean Capital Management Llc increased Assured Guaranty Ltd (AGO) stake by 25% reported in 2017Q3 SEC filing. Tegean Capital Management Llc acquired 80,000 shares as Assured Guaranty Ltd (AGO)’s stock declined 5.68%. The Tegean Capital Management Llc holds 400,000 shares with $15.10M value, up from 320,000 last quarter. Assured Guaranty Ltd now has $4.05B valuation. The stock decreased 1.04% or $0.37 during the last trading session, reaching $35.11. About 801,526 shares traded. Assured Guaranty Ltd. (NYSE:AGO) has risen 51.57% since March 14, 2017 and is uptrending. It has outperformed by 34.87% the S&P500.

Investors sentiment decreased to 0.94 in 2017 Q3. Its down 0.16, from 1.1 in 2017Q2. It fall, as 25 investors sold AGO shares while 93 reduced holdings. 44 funds opened positions while 86 raised stakes. 110.68 million shares or 2.19% less from 113.16 million shares in 2017Q2 were reported. Kahn Brothers Gru Incorporated De has 900,835 shares for 5.2% of their portfolio. Capital Fund Management Sa reported 0.05% in Assured Guaranty Ltd. (NYSE:AGO). 547,884 are held by Manufacturers Life Insurance Company The. Daiwa Securities Grp Inc Inc has invested 0.02% of its portfolio in Assured Guaranty Ltd. (NYSE:AGO). California Employees Retirement Systems holds 0.03% or 532,102 shares in its portfolio. Fifth Third Financial Bank reported 1,734 shares stake. M&T Bankshares stated it has 0% in Assured Guaranty Ltd. (NYSE:AGO). Parametric Assocs Limited Liability Co accumulated 392,052 shares. Dekabank Deutsche Girozentrale, Germany-based fund reported 96,467 shares. 1.77M were reported by Jpmorgan Chase. Rocky Mountain Advisers Limited has invested 0.04% in Assured Guaranty Ltd. (NYSE:AGO). Grantham Mayo Van Otterloo & Co Ltd Liability Corp holds 94,176 shares or 0.02% of its portfolio. Gideon Cap Advsrs Inc stated it has 0.63% in Assured Guaranty Ltd. (NYSE:AGO). Moreover, Cubist Systematic Strategies Ltd Llc has 0.16% invested in Assured Guaranty Ltd. (NYSE:AGO). Dupont reported 128,200 shares.

Since September 28, 2017, it had 0 insider purchases, and 1 sale for $38 activity. FREDERICO DOMINIC also sold $38 worth of Assured Guaranty Ltd. (NYSE:AGO) on Thursday, September 28.

Among 6 analysts covering Assured Guaranty (NYSE:AGO), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Assured Guaranty had 12 analyst reports since August 12, 2015 according to SRatingsIntel. The rating was maintained by UBS with “Buy” on Wednesday, October 4. The rating was initiated by Keefe Bruyette & Woods with “Buy” on Wednesday, December 20. The firm earned “Buy” rating on Tuesday, November 10 by UBS. The company was maintained on Monday, November 16 by M Partners. The firm earned “Hold” rating on Friday, June 9 by Keefe Bruyette & Woods. The stock of Assured Guaranty Ltd. (NYSE:AGO) earned “Mkt Perform” rating by Keefe Bruyette & Woods on Tuesday, February 28. The stock has “Buy” rating by BTIG Research on Friday, May 26. The rating was maintained by Macquarie Research with “Outperform” on Monday, November 9. Zacks downgraded the stock to “Buy” rating in Wednesday, August 12 report. Wood maintained Assured Guaranty Ltd. (NYSE:AGO) rating on Friday, April 7. Wood has “Hold” rating and $42 target.

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the United States and internationally. The company has market cap of $570.88 million. The Company’s drug candidates for treating chronic hepatitis C virus infection comprise Odalasvir, a NS5A inhibitor, which has completed Phase IIa clinical trials; ACH-3422, a NS5B nucleotide polymerase inhibitor; and Sovaprevir, a NS3 protease inhibitor that has completed Phase II clinical trial. It currently has negative earnings. The firm is also developing ACH-4471, a complement factor D inhibitor, which is in Phase I clinical trial to treat patients with paroxysmal nocturnal hemoglobinuria and C3G, a disease resulting from alternative pathway over-activation; and other factor D inhibitors.

The stock increased 2.22% or $0.09 during the last trading session, reaching $4.14. About 1.48M shares traded. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has declined 47.61% since March 14, 2017 and is downtrending. It has underperformed by 64.31% the S&P500.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: